ArticleFrontiers in ophthalmology2025
Exploring the role of orbital exenteration in survival among patients with severe rhino-orbital cerebral mucormycosis: a case series.
Article in Frontiers in ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhino-orbital cerebral mucormycosis (ROCM) is a rare, but potentially fatal opportunistic infection due to a fungus of the Mucorales sp. that involves infiltration of the sinuses, orbits, and central nervous system. Orbital exenteration (OE) is reserved for severe cases refractory to initial antifungal treatment and endoscopic sinus debridement, though there is currently no consensus on the ideal timing of OE and its impact on infection progression and survival. In this case series, we present three cases of similar, extensive ROCM that were candidates for OE after initial medical and surgical management with variable outcomes. We discuss that undergoing OE does not necessarily correlate with survival after ROCM infection and that the decision to proceed with exenteration should be personalized based on the status of a patient's comorbidities and the nature and extent of infectious spread. Globe-sparing OE may serve as a viable alternative for patients with localized, late-stage infection or reversible ROCM risk factors given vision preservation and less postoperative disfigurement with possibly comparable efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.